New anti-obesity drugs have the potential to transform public health, while obliterating demand for products and services from the medical, food and fitness industries.
Drugs developed by Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) appear to be the first truly effective diet treatments.
In one clinical trial, patients taking Eli Lilly’s soon-to-be-launched weight-loss drug lost about 50 pounds (23 kg).
Only about a third of those who started taking the drugs for obesity were still doing so a year later, according to one analysis.
Yet even as Novo, Lilly and others see their addressable markets expand, some companies will see theirs shrink.
Persons:
Lilly, George Frey, Eli Lilly, Eli Lilly’s, Novo, Wegovy, Kraft Heinz, Burger, LSEG, Michael Farrell, Zimmer Biomet, Smith, Peter Thal Larsen, Sharon Lam, Oliver Taslic
Organizations:
Novo Nordisk, Pharmacy, REUTERS, Reuters, TAM, Drugs, Alpha, Reuters Graphics Reuters, Cadbury, Mondelez, Fortune Business, Burger King, KFC, Yum Brands, Centers for Disease Control, Milken Institute, BMJ, Novo, Inspire Medical Systems, Novo Nordisk’s, WW International, Fashion, Thomson
Locations:
Provo , Utah, U.S, New, United States, Lilly, England